DE3650377D1 - Regulierung der retroviralen replikation, infektion und pathogenese. - Google Patents

Regulierung der retroviralen replikation, infektion und pathogenese.

Info

Publication number
DE3650377D1
DE3650377D1 DE3650377T DE3650377T DE3650377D1 DE 3650377 D1 DE3650377 D1 DE 3650377D1 DE 3650377 T DE3650377 T DE 3650377T DE 3650377 T DE3650377 T DE 3650377T DE 3650377 D1 DE3650377 D1 DE 3650377D1
Authority
DE
Germany
Prior art keywords
infection
pathogenesis
regulation
glucosidase
infected cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3650377T
Other languages
English (en)
Other versions
DE3650377T2 (de
Inventor
Larry Rohrschneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Publication of DE3650377D1 publication Critical patent/DE3650377D1/de
Application granted granted Critical
Publication of DE3650377T2 publication Critical patent/DE3650377T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DE3650377T 1985-12-23 1986-11-26 Regulierung der retroviralen replikation, infektion und pathogenese. Expired - Fee Related DE3650377T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81293785A 1985-12-23 1985-12-23
PCT/US1986/002586 WO1987003903A1 (en) 1985-12-23 1986-11-26 Regulating retroviral replication, infection, and pathogenesis

Publications (2)

Publication Number Publication Date
DE3650377D1 true DE3650377D1 (de) 1995-09-28
DE3650377T2 DE3650377T2 (de) 1996-02-22

Family

ID=37103004

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3650377T Expired - Fee Related DE3650377T2 (de) 1985-12-23 1986-11-26 Regulierung der retroviralen replikation, infektion und pathogenese.

Country Status (8)

Country Link
US (2) US5264356A (de)
EP (1) EP0252962B1 (de)
JP (1) JPS63501925A (de)
AT (1) ATE126696T1 (de)
AU (1) AU599381B2 (de)
CA (1) CA1306951C (de)
DE (1) DE3650377T2 (de)
WO (1) WO1987003903A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE126696T1 (de) * 1985-12-23 1995-09-15 Hutchinson Fred Cancer Res Regulierung der retroviralen replikation, infektion und pathogenese.
EP0282618A1 (de) * 1987-03-18 1988-09-21 Vereniging Het Nederlands Kanker Instituut 1-Deoxynojirimycin als Anti-HIV-Therapeutikum
ZA883925B (en) * 1987-06-08 1989-02-22 Merrell Dow Pharma Inhibitors of glycoprotein processing having anti-retroviral activity
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US5192772A (en) * 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
GB8827701D0 (en) * 1987-12-09 1988-12-29 Nippon Shinyaku Co Ltd Thrombolytic &c compositions
US4999360A (en) * 1987-12-21 1991-03-12 Monsanto Company Method of inhibiting virus
US5089520A (en) * 1987-12-21 1992-02-18 Monsanto Company Method of inhibiting virus
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
EP0322822B1 (de) * 1987-12-25 1992-11-11 Meiji Seika Kaisha Ltd. Verwendung von Lactamgruppe-enthaltenden Verbindungen zur Herstellung eines antiviralen Wirkstoffes
FR2632526B1 (fr) * 1988-06-10 1994-05-13 Pasteur Institut Composition pharmaceutique active sur les residus glucose de la glycoproteine gp 150
EP0350012A3 (de) * 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antivirale Zusammensetzung
AU618838B2 (en) * 1988-08-10 1992-01-09 Praxis Pharmaceuticals, Inc. Use of castanospermine as an anti-inflammatory and immunosuppressant agent
US5691346A (en) * 1988-08-10 1997-11-25 The Australian National University Castanospermine as an anti-inflammatory and immunosuppressant agent
EP0430983B1 (de) * 1988-08-10 1994-04-20 The Australian National University Verwendung von castanospermin als ein antientzündliches und immununterdrückendes mittel
US5043416A (en) * 1988-09-26 1991-08-27 Monsanto Company Method of inhibiting virus
US5310745A (en) * 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US4973602A (en) * 1988-11-03 1990-11-27 G. D. Searle & Co. Antiviral compounds and a method of use thereas
US4937357A (en) * 1988-11-03 1990-06-26 G. D. Searle & Co. Intermediates for antiviral compounds
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US4876268A (en) * 1988-11-03 1989-10-24 G. D. Searle & Co. Antiviral compounds and use thereof
US5221746A (en) * 1988-11-03 1993-06-22 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5144037A (en) * 1988-11-03 1992-09-01 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-d-glucitol derivatives
US4957926A (en) * 1988-12-22 1990-09-18 Monsanto Company Method of treating herpesviruses
EP0407701A3 (en) * 1989-05-15 1992-04-22 Fujisawa Pharmaceutical Co., Ltd. Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives
US4994572A (en) * 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5030638A (en) * 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5536732A (en) * 1990-04-27 1996-07-16 Merrell Pharmaceuticals Inc. N-derivatives of 1-deoxy nojirimycin
US5252587A (en) * 1990-04-27 1993-10-12 Merrell Dow Pharmaceuticals, Inc. N-derivatives of 1-deoxy nojirimycin
US5151519A (en) * 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
US5248779A (en) * 1991-06-17 1993-09-28 Monsanto Company Synthesis of nojirimycin derivatives
US5206251A (en) * 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5258518A (en) * 1992-04-01 1993-11-02 G. D. Searle & Co. 2-substituted tertiary carbinol derivatives of deoxynojirimycin
US5268482A (en) * 1992-04-01 1993-12-07 G. D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5216168A (en) * 1992-04-01 1993-06-01 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5342951A (en) * 1992-04-01 1994-08-30 G.D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5331096A (en) * 1992-04-01 1994-07-19 G. D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5658560A (en) * 1994-01-18 1997-08-19 Serikov; Vladimir B. Method of treating endotoxemia by administering tyloxapol
US5650413A (en) * 1995-06-07 1997-07-22 Glycodesign Inc. Derivatives of swainsonine, processes for their preparation and their use as therapeutic agents
DE19549015C1 (de) * 1995-12-28 1997-04-03 Siemens Ag Verfahren und Anordnung zur Überwachung eines abreißenden Flüssigkeitstrahls
WO1998009981A1 (en) * 1996-09-09 1998-03-12 Wisconsin Alumni Research Foundation Human salivary proteins and fragments thereof having alpha-glucosidase inhibitory activity
AU736668B2 (en) * 1996-10-01 2001-08-02 Glycodesign Inc. Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6395745B1 (en) 1997-04-15 2002-05-28 Glycodesign, Inc. Alkaloid halide salts of swainsonine and methods of use
AU9617298A (en) * 1997-10-24 1999-05-17 Glycodesign Inc. Synthesis of swainsonine salts
AU753336B2 (en) 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
BR9813508A (pt) * 1997-12-11 2000-10-03 Univ Oxford Inibição de replicação viral associada com membrana
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
TR200002323T2 (tr) 1998-02-12 2000-12-21 G.D. Searle & Co. Hepatit virüs enfeksiyonlarının tedavi edilmesi için N-ikameli-1,5-dideoksi 1,5-imino-D-glusitol bileşiklerinin kullanımı
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ATE402701T1 (de) 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
US6515028B1 (en) 1999-02-12 2003-02-04 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
US7816560B1 (en) * 1999-08-10 2010-10-19 Thomas Jefferson University Long chain n-alkyl compounds and oxa-derivatives thereof
US20050119310A1 (en) * 2000-02-14 2005-06-02 Mueller Richard A. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
KR100446483B1 (ko) 2000-03-31 2004-09-01 미시간 스테이트 유니버시티 옥심 또는 이민으로부터 1,5-디데옥시-1,5-이미노 헥시톨제조방법
WO2003096985A2 (en) * 2002-05-15 2003-11-27 University Of Utah Research Foundation 3d structure of the tsg101 uev domain
US7342010B2 (en) * 2004-11-15 2008-03-11 Board Of Trustees Of Michigan State University 2-thiaquinolizidines and process for the preparation thereof
US20070099823A1 (en) * 2005-10-28 2007-05-03 Board Of Trustees Of The University Of Arkansas Inhibitors of sporeforming pathogens and applications of the same
JP2009545621A (ja) * 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
US20090252785A1 (en) * 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
KR20120059447A (ko) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
KR20180053775A (ko) 2010-04-23 2018-05-23 제넨테크, 인크. 이종다량체 단백질의 생산
KR101351181B1 (ko) 2010-05-11 2014-01-14 가천대학교 산학협력단 단핵식세포계 세포 내에서 ａｇｅ-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE902199A (fr) * 1984-10-29 1985-07-31 Vira Tek Inc Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
CA1327970C (en) * 1985-05-24 1994-03-22 Paul S. Liu Isolation of castanospermine and its use as an antidiabetic agent
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
ATE126696T1 (de) * 1985-12-23 1995-09-15 Hutchinson Fred Cancer Res Regulierung der retroviralen replikation, infektion und pathogenese.
US4857315A (en) * 1986-09-29 1989-08-15 Mount Sinai Hospital Corporation Compositions containing golgi alpha-mannosidase II inhibitors
ZA883925B (en) * 1987-06-08 1989-02-22 Merrell Dow Pharma Inhibitors of glycoprotein processing having anti-retroviral activity
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
KR100192862B1 (ko) * 1991-01-10 1999-06-15 슈테펜엘.네스비트 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제

Also Published As

Publication number Publication date
WO1987003903A1 (en) 1987-07-02
JPS63501925A (ja) 1988-08-04
EP0252962A4 (en) 1992-09-09
EP0252962B1 (de) 1995-08-23
ATE126696T1 (de) 1995-09-15
CA1306951C (en) 1992-09-01
US5264356A (en) 1993-11-23
US5643888A (en) 1997-07-01
AU7362387A (en) 1988-06-02
AU599381B2 (en) 1990-07-19
DE3650377T2 (de) 1996-02-22
EP0252962A1 (de) 1988-01-20

Similar Documents

Publication Publication Date Title
DE3650377D1 (de) Regulierung der retroviralen replikation, infektion und pathogenese.
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
ES2192201T3 (es) Compuestos de piranona utiles para el tratamiento de infecciones retrovirales.
ES2031523T3 (es) Agentes diureticos de glutaramida espiro-sustituida.
SE8800731D0 (sv) Phenyl carbamate
DK0413622T3 (da) Albuminderivater med terapeutiske virkninger
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
ES479615A1 (es) Un procedimiento para la preparacion de nuevos derivados de glicerol.
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2058417T3 (es) Combinaciones herbicidas sinergisticas y metodo de aplicacion.
ES2057262T3 (es) Derivados del cromano.
ATE14222T1 (de) Sekundaere aethanolamine, ihre herstellung und ihre verwendung in pharmazeutischen zusammensetzungen.
ES2045484T3 (es) Nuevos derivados de la vitamina d: aplicaciones terapeuticas y a las dosificaciones de los metabolitos de la vitamina d.
FR2421614A1 (fr) Composition pharmaceutique a base de 2-(7'-theophyllinomethyl)-1,3-dioxolane
KR900005993A (ko) 레트로바이러스에 의해 유발되는 질병 치료용 약제
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
DK521685D0 (da) Spergualin-derivater og anvendelse deraf til fremstilling af laegemidler med immunosuppressiv virkning
ATE81775T1 (de) Pharmazeutische zusammensetzungen.
ATE27813T1 (de) N-substituierte 1-(4'-alkylsulfonylphenyl)-2amino-1,3-propanediol-derivate.
IT1210926B (it) Derivati della 1-metil-5-nitro-imidazolina e composizioni terapeutiche che li comprendono come principio attivo.
IE44461L (en) Piperazinyluracil salts

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee